ATE416769T1 - Neue verwendung von glutamat-antagonisten zur behandlung von krebs - Google Patents

Neue verwendung von glutamat-antagonisten zur behandlung von krebs

Info

Publication number
ATE416769T1
ATE416769T1 AT05012871T AT05012871T ATE416769T1 AT E416769 T1 ATE416769 T1 AT E416769T1 AT 05012871 T AT05012871 T AT 05012871T AT 05012871 T AT05012871 T AT 05012871T AT E416769 T1 ATE416769 T1 AT E416769T1
Authority
AT
Austria
Prior art keywords
glutamate
new use
cancer
treat cancer
glutamate antagonists
Prior art date
Application number
AT05012871T
Other languages
English (en)
Inventor
Hrissanthi Ikonomidou
Original Assignee
Hrissanthi Ikonomidou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hrissanthi Ikonomidou filed Critical Hrissanthi Ikonomidou
Application granted granted Critical
Publication of ATE416769T1 publication Critical patent/ATE416769T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05012871T 1998-10-28 1999-10-22 Neue verwendung von glutamat-antagonisten zur behandlung von krebs ATE416769T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98250380A EP1002535A1 (de) 1998-10-28 1998-10-28 Neue Verwendung von Glutamat-Antagonisten zur Behandlung von Krebs

Publications (1)

Publication Number Publication Date
ATE416769T1 true ATE416769T1 (de) 2008-12-15

Family

ID=8234602

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05012871T ATE416769T1 (de) 1998-10-28 1999-10-22 Neue verwendung von glutamat-antagonisten zur behandlung von krebs

Country Status (7)

Country Link
US (3) US6797692B1 (de)
EP (4) EP1002535A1 (de)
JP (1) JP2002528415A (de)
AT (1) ATE416769T1 (de)
AU (1) AU6475099A (de)
DE (1) DE69940080D1 (de)
WO (1) WO2000024395A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69922997T2 (de) * 1998-12-04 2005-12-15 Neurosearch A/S Verwendung von isatinderivaten als ionenkanalaktivierende mittel
CN1298704C (zh) * 2000-01-24 2007-02-07 神经研究公司 具有神经营养活性的靛红衍生物
EP1157682A1 (de) * 2000-05-25 2001-11-28 Cilag AG Blisterpackung für Topiramattabletten
DE10112926B4 (de) * 2001-03-13 2005-11-10 Schebo Biotech Ag Verwendung von Aminooxyacetat zur Tumorbehandlung
AU2002307049A1 (en) * 2001-04-02 2002-10-15 Brown University Research Foundation Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
KR100537436B1 (ko) * 2001-05-31 2005-12-21 김익수 복어 알 추출액을 함유하는 항암 치료용 약학 조성물
EP1427404A4 (de) * 2001-08-20 2005-10-26 Maiken Nedergaard Behandlung von glia-tumoren mit glutamat-antagonisten
MXPA04009496A (es) * 2002-03-29 2005-01-25 Yamanouchi Pharma Co Ltd Remedio para glioblastoma.
WO2004035580A1 (en) * 2002-10-21 2004-04-29 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
AU2003297639A1 (en) * 2002-12-02 2004-06-23 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
KR100581344B1 (ko) * 2003-05-02 2006-05-23 주식회사디엔에이링크 텔로머라제 활성 억제용 조성물
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US8835473B2 (en) * 2004-04-16 2014-09-16 Rutgers, The State University Of New Jersey Methods and compositions for treating cancer
FR2872358B1 (fr) * 2004-06-23 2006-09-29 Comsis Sa Decodeur numerique pour systeme de transmission numerique sans fil utilisant un code spatio-temporel lineaire
GB0416730D0 (en) 2004-07-27 2004-09-01 Novartis Ag Organic compounds
US20080194698A1 (en) * 2005-03-07 2008-08-14 Michael Hermanussen Nmda Receptor Antagonists in the Medical Intervention of Metabolic Disorders
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US8592168B2 (en) * 2005-04-19 2013-11-26 Trustees Of Darmouth College Methods for diagnosing and treating neuroendocrine cancer
US7842468B2 (en) 2005-04-19 2010-11-30 Trustees Of Dartmouth College Methods for diagnosing and treating neuroendocrine cancer
US8415109B2 (en) * 2005-04-19 2013-04-09 Trustees Of Dartmouth College Methods for diagnosing and treating neuroendocrine cancer
US9694072B2 (en) 2005-04-19 2017-07-04 Trustees Of Dartmouth College Methods for diagnosing and treating neuroendocrine cancer
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
US7732447B2 (en) 2006-06-22 2010-06-08 Cephalon, Inc. Fused [d]pyridazin-7-ones
US8889950B2 (en) 2006-07-28 2014-11-18 The George Washington University Repression of AtGLR3.2 increases plant biomass
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
WO2009016486A2 (en) * 2007-08-02 2009-02-05 Compugen, Ltd Use of nmda receptor antagonists for treatment of urologic tumors
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
US20090210967A1 (en) * 2007-10-17 2009-08-20 Turano Frank J Glutamate Receptors as Regulators of Carbon Transport, Mobilization, Distribution, Reallocation, and Partitioning in Higher Plants
GB0722274D0 (en) * 2007-11-13 2007-12-27 Ludwig Inst Cancer Res New therapeutic method
KR101220455B1 (ko) 2008-03-12 2013-01-31 김현호 산왕거미 추출물을 포함하는 면역세포증가용 약학적 조성물
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
ES2526651T3 (es) 2008-07-03 2015-01-14 Monsanto Technology Llc Combinaciones de tensioactivos de sacáridos derivatizados y tensioactivos de óxido de eteramina como adyuvantes de herbicidas
CN101569617A (zh) * 2009-06-11 2009-11-04 辽宁利锋科技开发有限公司 具有金刚烷结构药物及其衍生物和类似物抗肿瘤新适应症的应用
KR101390023B1 (ko) * 2009-06-18 2014-04-29 화이자 인코포레이티드 키누레닌 아미노트랜스퍼라제 ｉｉ 억제제로서 이환식 및 삼환식 화합물
WO2011006170A2 (en) * 2009-07-10 2011-01-13 Microbial-Vac Systems, Inc. System and method for cleaning contaminant collection equipment
GB0915877D0 (en) * 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
US9526911B1 (en) * 2010-04-27 2016-12-27 Lazure Scientific, Inc. Immune mediated cancer cell destruction, systems and methods
JP5562716B2 (ja) * 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
US10864271B2 (en) 2012-02-15 2020-12-15 Rutgers, The State University Of New Jersey Combination therapy using riluzole to enhance tumor sensitivity to ionizing radiation
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2018132829A1 (en) * 2017-01-16 2018-07-19 Drexel University Novel glutamate transporter activators and methods using same
US20210177827A1 (en) * 2017-10-25 2021-06-17 Children`S Medical Center Corporation Papd5 inhibitors and methods of use thereof
JP2019151621A (ja) * 2018-02-28 2019-09-12 学校法人藤田学園 Ｋａｔ阻害活性を有する化合物を含有するがん治療用組成物
WO2020023800A1 (en) * 2018-07-27 2020-01-30 With Great Power, Llc Clinical methods and pharmaceutical compositions employing ampa receptor antagonists to treat glioblastoma and other cancers
US20220313701A1 (en) * 2019-05-02 2022-10-06 Constellation Pharmaceuticals, Inc. Modulators of trex1
WO2021011876A2 (en) * 2019-07-18 2021-01-21 The Wistar Institute Of Anatomy And Biology Modulators of excitatory amino acid transporters and methods using same
WO2022197767A1 (en) * 2021-03-17 2022-09-22 Memorial Sloan-Kettering Cancer Center Methods for improving survival in lung cancer patients via ketamine oncoprotection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
GB8810173D0 (en) * 1988-04-29 1988-06-02 Norsk Hydro As Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5039528A (en) * 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US5710179A (en) * 1995-04-05 1998-01-20 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antitumor agent
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US6046180A (en) * 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors

Also Published As

Publication number Publication date
JP2002528415A (ja) 2002-09-03
US20050054650A1 (en) 2005-03-10
EP1649857A3 (de) 2007-03-28
AU6475099A (en) 2000-05-15
US7247610B2 (en) 2007-07-24
DE69940080D1 (de) 2009-01-22
WO2000024395A1 (en) 2000-05-04
US6797692B1 (en) 2004-09-28
EP1586321A1 (de) 2005-10-19
EP1124553A1 (de) 2001-08-22
EP1586321B1 (de) 2008-12-10
EP1649857A2 (de) 2006-04-26
EP1002535A1 (de) 2000-05-24
US20050054619A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
ATE416769T1 (de) Neue verwendung von glutamat-antagonisten zur behandlung von krebs
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
WO2000001376A3 (en) Pharmaceutical compositions and their uses for treatment of demyelinating disorders
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
EA200300354A1 (ru) Хинолиноновые производные в качестве ингибиторов тирозинкиназы
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
HRP20030071B1 (hr) Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
RU98105512A (ru) Применение производных пиримидина для профилактики рака отдельно или в комбинации с другими терапевтическими мероприятиями
BR9811482A (pt) Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
DE69940951D1 (de) Nd wachstumshemmende mittel
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
ATE230993T1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
EE03526B1 (et) Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
BRPI0414777A (pt) compostos, composições farmacêuticas, uso de um ou mais compostos, e, método de tratar um paciente que sofre de um distúrbio
ATE232094T1 (de) Verwendung eines 5ht2 rezeptor-antagonisten zur behandlung von schlafapnoe
BRPI0417946A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties